FRNMFreenome Inc. Common stock

NAS · US · Healthcare · Diagnostics & Research · freenome.com

13.81USD+1.32%Mkt Cap: 1.47B $P/E: —3d ago

Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap1.47B $

Enterprise Value1.89B $

Revenue (TTM)34.24M $

Gross Profit28.46M $

Net Income (TTM)-219.34M $

Revenue/Share1.289 USD

Last Price13.81 USD

Fiscal Year EndDec 2025

MR QuarterMar 2026

Employees363

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-5.63

PEG—

EV/EBITDA-9.38

EV/Revenue55.08

P/S41.87

P/B-0.27

EPS (TTM)-2.05

EPS (Forward)-2.40

52W Range

9.95085% of range14.47

52W High14.47 USD

52W Low9.950 USD

Profitability

Gross Margin93.61%

Oper. Margin-1474.30%

EBITDA Margin0.00%

Profit Margin-721.31%

ROE17.36%

ROA-43.26%

Growth

Revenue Growth971.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-110.67M $

CapEx (TTM)21.05M $

FCF Margin—

FCF Yield—

Net Debt167.29M $

Net Debt/EBITDA-0.83

Balance Sheet

Debt/Equity-0.25

Current Ratio1.89

Quick Ratio1.76

Book Value/Sh-50.4000 USD

Cash/Share5.461 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)17.25 USD

Upside (mean)+24.9%

Target Range17.00 USD – 18.00 USD

$17.00+24.9% to mean$18.00

# Analysts4

Ownership

Shares Out.106.10M

Float18.69M

Insiders26.02%

Institutions38.30%

Short Interest

Short Ratio0.6d

Short % Out.0.42%

Shares Short445.74K

Technical

SMA 5011.46 (+20.5%)

SMA 20011.82 (+16.9%)

Beta0.35

S&P 52W Chg18.16%

Avg Vol (30d)670.62K

Avg Vol (10d)1.05M

Technical Indicators

RSI (14)70.7

MACD0.4462

MACD Signal0.1636

MACD Hist.+0.2826

BB Upper13.76 USD

BB Middle11.62 USD

BB Lower9.479 USD

BB Width36.83%

ATR (14)0.8146 USD

Vol Ratio (20d)0.84x